Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
$1.09
-0.9%
$1.24
$0.87
$2.55
$20.56M0.43241,179 shs88,966 shs
Longeveron Inc. stock logo
LGVN
Longeveron
$1.69
-3.2%
$1.35
$1.14
$4.29
$25.16M0.21303,228 shs225,972 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.65
$3.37
$2.57
$6.88
$22.55M0.628,674 shs1,837 shs
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
$1.39
-26.1%
$0.94
$0.55
$1,200.00
$7.41MN/A3.49 million shs3.86 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-1.79%-3.51%-6.78%-14.73%-10.93%
Longeveron Inc. stock logo
LGVN
Longeveron
+4.19%+19.18%+51.30%+6.75%-40.21%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+5.19%+6.41%+9.61%+26.30%-36.96%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
+29.66%+79.05%+173.30%-97.85%+187,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
2.2041 of 5 stars
3.53.00.00.00.61.70.6
Longeveron Inc. stock logo
LGVN
Longeveron
2.8135 of 5 stars
3.64.00.00.01.11.70.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.6317 of 5 stars
0.04.00.00.00.01.70.6
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
3.00
Buy$8.50672.73% Upside
Longeveron Inc. stock logo
LGVN
Longeveron
3.25
Buy$8.67408.31% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PLRZ, LGVN, CMMB, and NAII Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.00
(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/A$0.72 per shareN/A
Longeveron Inc. stock logo
LGVN
Longeveron
$2.39M10.65N/AN/A$1.47 per share1.16
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$125.48M0.18N/AN/A$13.32 per share0.27
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/AN/A$315.05 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$13.94M-$0.76N/AN/AN/AN/A-106.70%-82.18%8/20/2025 (Estimated)
Longeveron Inc. stock logo
LGVN
Longeveron
-$15.97M-$6.28N/AN/AN/A-760.72%-85.07%-70.74%8/13/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/29/2025 (Estimated)
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
-$1.54MN/A0.00N/AN/AN/AN/AN/A

Latest PLRZ, LGVN, CMMB, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/20/2025Q2 2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$0.20N/AN/AN/AN/AN/A
8/13/2025Q2 2025
Longeveron Inc. stock logo
LGVN
Longeveron
-$0.35N/AN/AN/A$0.41 millionN/A
5/15/2025Q1 2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$0.20-$0.14+$0.06-$0.14N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/AN/A
Longeveron Inc. stock logo
LGVN
Longeveron
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/A
5.33
5.33
Longeveron Inc. stock logo
LGVN
Longeveron
N/A
5.61
5.61
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A
10.16
10.16

Institutional Ownership

CompanyInstitutional Ownership
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
46.05%
Longeveron Inc. stock logo
LGVN
Longeveron
10.01%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A

Insider Ownership

CompanyInsider Ownership
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
11.91%
Longeveron Inc. stock logo
LGVN
Longeveron
11.20%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
2018.86 million16.61 millionNot Optionable
Longeveron Inc. stock logo
LGVN
Longeveron
2014.93 million13.26 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A5.33 millionN/AN/A

Recent News About These Companies

Polyrizon Announces Receipt of Nasdaq Delisting Notice

New MarketBeat Followers Over Time

Media Sentiment Over Time

Chemomab Therapeutics stock logo

Chemomab Therapeutics NASDAQ:CMMB

$1.09 -0.01 (-0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$1.10 +0.00 (+0.46%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Longeveron stock logo

Longeveron NASDAQ:LGVN

$1.68 -0.06 (-3.16%)
Closing price 03:59 PM Eastern
Extended Trading
$1.70 +0.01 (+0.59%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.62 -0.03 (-0.82%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Polyrizon stock logo

Polyrizon NASDAQ:PLRZ

$1.39 -0.49 (-26.06%)
As of 04:00 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.